Arvinas Inc (ARVN)

$8.39 +0.19 (2.32%)
Market Cap 541.33M
Revenue (ttm) 262.60M
Net Income (ttm) -80.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.77%
Debt to Equity Ratio 0.00
Volume 643,600
Avg Vol 874,226
Day's Range N/A - N/A
Shares Out 64.52M
Stochastic %K 76%
Beta 1.74
Analysts Sell
Price Target $15.00

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
BullDonald
BullDonald Jul. 2 at 2:18 PM
$DPRO $ARVN $DPRO $BBAI $VNDA Go Greeeeen
0 · Reply
BullDonald
BullDonald Jun. 30 at 3:46 PM
$ARVN finally at My AVG, Lets GO
0 · Reply
mmdetritus
mmdetritus Jun. 29 at 6:29 PM
$ARVN No comment here on the departure of Berkowitz? It's not so surprising, given this is a fairly big year of refocusing. It seems orderly enough. Still. The guy was only around for a couple of years--was his main goal to get VEPPANU through and, since he's done with that... ?
1 · Reply
BullDonald
BullDonald Jun. 27 at 10:01 PM
$ARVN will spike violently on positive oncology data , we got multiple data read out. Oncology price spike hits diffrent .
1 · Reply
buyandsold
buyandsold Jun. 24 at 6:46 PM
Who is the shittiest money-burning management out of the following four retrobrates $KROS $PRTA $ARVN and $SPRO I rank them with the worst offender first in my opinion. I own the second and fourth offenders only. But I'm super tempted to try again with Kereos. There must be a way for me to get my hands on that Takeda money.
2 · Reply
BullDonald
BullDonald Jun. 23 at 4:30 PM
$ARVN I am still need to add 10K shares. seems revershal is on the card. If it crosses 8 and holds ! it will be confirnmed.
0 · Reply
diegosan21
diegosan21 Jun. 23 at 2:17 PM
$ARVN looking good
0 · Reply
Biotech80
Biotech80 Jun. 22 at 2:06 PM
$ARVN
0 · Reply
BullDonald
BullDonald Jun. 18 at 1:33 PM
$ARVN We got the Bottom at 7 👍
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 17 at 11:17 AM
$RIGL $ARVN $PFE
0 · Reply
Latest News on ARVN
Arvinas Transcript: AGM 2026

Jun 24, 2026, 8:00 AM EDT - 10 days ago

Arvinas Transcript: AGM 2026

Arvinas Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 4 weeks ago

Arvinas Transcript: Jefferies Global Healthcare Conference 2026

Arvinas to Present at Jefferies Global Healthcare Conference

May 29, 2026, 4:01 PM EDT - 5 weeks ago

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas Employees Give Back During Company-wide Impact Day

May 18, 2026, 10:30 AM EDT - 6 weeks ago

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas price target raised to $16 from $14 at BofA

2026-05-13T19:22:15.000Z - 7 weeks ago

Arvinas price target raised to $16 from $14 at BofA

PFE RIGL

Arvinas price target raised to $18 from $16 at BTIG

2026-05-13T12:47:37.000Z - 7 weeks ago

Arvinas price target raised to $18 from $16 at BTIG

RIGL

Arvinas price target raised to $20 from $18 at Barclays

2026-05-13T09:00:59.000Z - 7 weeks ago

Arvinas price target raised to $20 from $18 at Barclays

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

2026-05-12T17:45:03.000Z - 7 weeks ago

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

PFE RIGL

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

2026-05-12T16:35:26.000Z - 7 weeks ago

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

PFE RIGL

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

2026-05-12T13:02:04.000Z - 7 weeks ago

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

PFE RIGL

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

PFE RIGL

Arvinas Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Arvinas Earnings Call Transcript: Q1 2026

Arvinas Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Arvinas Quarterly report: Q1 2026

Arvinas Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Arvinas Earnings release: Q1 2026

Arvinas reports Q1 EPS (90c), consensus (63c)

2026-05-12T11:49:11.000Z - 7 weeks ago

Arvinas reports Q1 EPS (90c), consensus (63c)

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:05 AM EDT - 7 weeks ago

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

PFE

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

May 5, 2026, 7:00 AM EDT - 2 months ago

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas management to meet with BTIG

2026-05-04T19:30:43.000Z - 2 months ago

Arvinas management to meet with BTIG

Arvinas price target raised to $24 from $21 at Citi

2026-05-04T09:10:10.000Z - 2 months ago

Arvinas price target raised to $24 from $21 at Citi

Arvinas gets early approval for Vepdeg, says Truist

2026-05-01T17:15:17.000Z - 2 months ago

Arvinas gets early approval for Vepdeg, says Truist

Arvinas trading resumes

2026-05-01T17:05:16.000Z - 2 months ago

Arvinas trading resumes

Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC

2026-05-01T16:51:08.000Z - 2 months ago

Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC

PFE

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

May 1, 2026, 12:43 PM EDT - 2 months ago

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 2 months ago

US FDA approves Pfizer, Arvinas' breast cancer drug

PFE

Arvinas trading halted, news pending

2026-05-01T15:27:03.000Z - 2 months ago

Arvinas trading halted, news pending

Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Arvinas Proxy statement: Proxy filing

Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Arvinas Proxy statement: Proxy filing

Arvinas price target raised to $21 from $18 at Citi

2026-03-19T10:11:49.000Z - 3 months ago

Arvinas price target raised to $21 from $18 at Citi

Arvinas presents data from Phase 1 clinical trial of ARV-102

2026-03-18T11:10:49.000Z - 3 months ago

Arvinas presents data from Phase 1 clinical trial of ARV-102

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 11, 2026, 7:00 AM EDT - 4 months ago

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Arvinas Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 11:00 AM EDT - 4 months ago

Arvinas Transcript: Barclays 28th Annual Global Healthcare Conference

Arvinas Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 4 months ago

Arvinas Transcript: Leerink Global Healthcare Conference 2026

Arvinas price target raised to $18 from $15 at Citi

2026-03-05T10:41:31.000Z - 4 months ago

Arvinas price target raised to $18 from $15 at Citi

Arvinas Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 4 months ago

Arvinas Transcript: TD Cowen 46th Annual Health Care Conference

Arvinas price target raised to $11 from $9 at Wedbush

2026-02-25T13:39:54.000Z - 4 months ago

Arvinas price target raised to $11 from $9 at Wedbush

Arvinas Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Arvinas Earnings Call Transcript: Q4 2025

Arvinas Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Arvinas Annual report: Q4 2025

Arvinas Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Arvinas Earnings release: Q4 2025

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 7:00 AM EST - 4 months ago

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 4 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 17, 2026, 7:00 AM EST - 4 months ago

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Feb 12, 2026, 7:00 AM EST - 5 months ago

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Dec 6, 2025, 8:05 AM EST - 7 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 11:00 AM EST - 7 months ago

Arvinas Transcript: Piper Sandler 37th Annual Healthcare Conference

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 7 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 24, 2025, 7:00 AM EST - 7 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:30 AM EST - 8 months ago

Arvinas Transcript: Jefferies London Healthcare Conference 2025

Arvinas Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 2:30 PM EST - 8 months ago

Arvinas Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Arvinas Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Arvinas Earnings Call Transcript: Q3 2025

Arvinas Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Arvinas Quarterly report: Q3 2025

Arvinas Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Arvinas Earnings release: Q3 2025

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 8 months ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 4:00 PM EST - 8 months ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 8 months ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 4:00 PM EDT - 9 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 9 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Oct 20, 2025, 4:15 AM EDT - 9 months ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 13, 2025, 7:00 AM EDT - 9 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 5, 2025, 2:00 PM EDT - 9 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 9 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Sep 17, 2025, 5:50 PM EDT - 10 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 17, 2025, 4:30 PM EDT - 10 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 8, 2025, 4:05 PM EDT - 11 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Arvinas Earnings Call Transcript: Q2 2025

Arvinas Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Arvinas Quarterly report: Q2 2025

Arvinas Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Arvinas Earnings release: Q2 2025

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

Arvinas Transcript: Jefferies Global Healthcare Conference 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Jun 5, 2025, 8:28 AM EDT - 1 year ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Arvinas Transcript: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Transcript: Study Update

Arvinas Press release: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Press release: Study Update

Arvinas Slides: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Slides: Study Update

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

May 31, 2025, 8:06 AM EDT - 1 year ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025, 8:00 AM EDT - 1 year ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

BullDonald
BullDonald Jul. 2 at 2:18 PM
$DPRO $ARVN $DPRO $BBAI $VNDA Go Greeeeen
0 · Reply
BullDonald
BullDonald Jun. 30 at 3:46 PM
$ARVN finally at My AVG, Lets GO
0 · Reply
mmdetritus
mmdetritus Jun. 29 at 6:29 PM
$ARVN No comment here on the departure of Berkowitz? It's not so surprising, given this is a fairly big year of refocusing. It seems orderly enough. Still. The guy was only around for a couple of years--was his main goal to get VEPPANU through and, since he's done with that... ?
1 · Reply
BullDonald
BullDonald Jun. 27 at 10:01 PM
$ARVN will spike violently on positive oncology data , we got multiple data read out. Oncology price spike hits diffrent .
1 · Reply
buyandsold
buyandsold Jun. 24 at 6:46 PM
Who is the shittiest money-burning management out of the following four retrobrates $KROS $PRTA $ARVN and $SPRO I rank them with the worst offender first in my opinion. I own the second and fourth offenders only. But I'm super tempted to try again with Kereos. There must be a way for me to get my hands on that Takeda money.
2 · Reply
BullDonald
BullDonald Jun. 23 at 4:30 PM
$ARVN I am still need to add 10K shares. seems revershal is on the card. If it crosses 8 and holds ! it will be confirnmed.
0 · Reply
diegosan21
diegosan21 Jun. 23 at 2:17 PM
$ARVN looking good
0 · Reply
Biotech80
Biotech80 Jun. 22 at 2:06 PM
$ARVN
0 · Reply
BullDonald
BullDonald Jun. 18 at 1:33 PM
$ARVN We got the Bottom at 7 👍
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 17 at 11:17 AM
$RIGL $ARVN $PFE
0 · Reply
BullDonald
BullDonald Jun. 12 at 3:49 PM
$ARVN 🔥
0 · Reply
NewGuyHere94
NewGuyHere94 Jun. 10 at 9:39 PM
$ARVN will be a slow rise again, quick 50% drop in the last few months. But more to come
1 · Reply
Jtlo
Jtlo Jun. 10 at 2:00 PM
$ARVN reversal?
0 · Reply
BullDonald
BullDonald Jun. 8 at 7:52 PM
$ARVN Added at 7.19
0 · Reply
BullDonald
BullDonald Jun. 8 at 5:10 PM
$ARVN will it go to below 7, I need some
0 · Reply
LouisianaOil
LouisianaOil Jun. 8 at 12:16 AM
$ARVN very poor cash position. Needs partners for everything
2 · Reply
BullDonald
BullDonald Jun. 5 at 7:51 PM
$ARVN Added again.
0 · Reply
Jtlo
Jtlo Jun. 5 at 6:17 PM
$ARVN I’m in fuck it
0 · Reply
MarketBeat
MarketBeat Jun. 5 at 4:12 PM
https://marketbeat.com/a/8695000/ $ARVN Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
0 · Reply
NewGuyHere94
NewGuyHere94 Jun. 5 at 12:35 PM
$ARVN might be time to reload
0 · Reply
Jtlo
Jtlo Jun. 5 at 10:31 AM
$ARVN getting good to enter.
0 · Reply
BullDonald
BullDonald Jun. 4 at 8:49 PM
$ARVN seems this is the stability range. Below 7 would work to load up more.
0 · Reply